Christopher J. Melani, M.D.

Team Member of:
Dr. Melani is a Staff Cinician and a clinical researcher specializing in lymphoma. His areas of interest include the use of novel therapies and drug combinations for the treatment of lymphomas as well as novel methods of molecular monitoring of disease and response to treatment, such as circulating tumor DNA (ctDNA).
1) lymphoma, 2) clinical trials, 3) novel drug use
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room 4N115
Bethesda, Maryland 20892
Ph: 301-814-7117
christopher.melani@nih.gov
-
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0014Investigator Christopher J. Melani, M.D. -
Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-17-C-0127Investigator Christopher J. Melani, M.D.Share this trial: Referral ContactsContact Name Phone Number
- Novel use of targeted therapies and immunotherapy in lymphoma.
- Molecular features of high-risk follicular lymphoma.
- Use of FDG-PET and management of mediastinal lymphomas.
- Use of novel methods of molecular monitoring, such as circulating tumor DNA (ctDNA), in lymphoma.
- Molecular features and novel treatment of primary CNS lymphoma (PCNSL)
Selected Recent Publications
- New Engl J Med. 377(1): 89-91, 2017. [ Journal Article ]
-
DA-EPOCH-R in Primary Mediastinal B-Cell Lymphoma; Analysis of End of Therapy FDG-PET and Outcome.Blood. in press, 2017. [ Journal Article ]
- Oncology (Williston Park, NY). 30(8): 731-8, 2016. [ Journal Article ]
- Cancer Cell. 31(6): 833-843, 2017. [ Journal Article ]
- Leuk Lymphoma. 22: 1-4, 2017. [ Journal Article ]
Dr. Melani earned a B.S. in biology with a minor in psychology from The Pennsylvania State University in University Park, PA in 2007. His medical training was conducted at Drexel University College of Medicine in Philadelphia, PA where he earned his M.D. in 2011. Dr. Melani's internship and residency training were performed at Johns Hopkins Hospital in Baltimore, MD from 2011 to 2014. He undertook fellowship training in hematology/oncology at NCI/NHLBI in Bethesda, MD from 2014 to 2017. Currently, he is employed as a Staff Clinician in the Lymphoid Malignancies Branch of the NCI under the mentorship of Dr. Wyndham H. Wilson.